Clinical PET in oncology: not only FDG
Authors:
- Cristina NanniCNCristina Nanni
- Domenico RubelloDRDomenico Rubello
- Adil Al-NahhasAAAdil Al-Nahhas
- Stefano FantiSFStefano Fanti
- 1 September 2006
- journal article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 27 (9) , 685-688
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- PET and prostate cancerWorld Journal of Urology, 2004
- 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PETEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic valueEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- Role of 11-C-methionine positron emission tomography for the delineation of the tumor volume in pharyngo-laryngeal squamous cell carcinoma: comparison with FDG-PET and CTRadiotherapy and Oncology, 2004
- C-Choline Positron Emission Tomography for the Evaluation after Treatment of Localized Prostate CancerEuropean Urology, 2003
- Value of [ 11 C]choline-Positron Emission Tomography for Re-Staging Prostate Cancer: A Comparison With [ 18 F]fluorodeoxyglucose-Positron Emission TomographyJournal of Urology, 2003
- Positive [11C]Choline and Negative [18F]FDG with Positron Emission Tomography in Recurrence of Prostate CancerAmerican Journal of Roentgenology, 2002
- Pheochromocytomas: Detection with18F DOPA Whole-Body PET—Initial ResultsRadiology, 2002
- Whole-Body18F Dopa PET for Detection of Gastrointestinal Carcinoid TumorsRadiology, 2001
- Pancreatic neuroendocrine tumors: diagnosis with PET.Radiology, 1995